x
Filter:
Filters applied
- Opioids
- Baron, RalfRemove Baron, Ralf filter
Author
- Audette, Joseph1
- Dworkin, Robert H1
- Gilron, Ian1
- Gourlay, Geoffrey K1
- Haanpää, Maija L1
- Jensen, Troels1
- Kent, Joel L1
- Krane, Elliot J1
- LeBel, Alyssa A1
- Levy, Robert M1
- Mackey, Sean C1
- Mayer, John1
- Miaskowski, Christine1
- O'Connor, Alec B1
- Raja, Srinivasa N1
- Rice, Andrew SC1
- Schmader, Kenneth E1
- Stacey, Brett1
- Stanos, Steven1
- Treede, Rolf-Detlef1
- Turk, Dennis C1
- Walco, Gary A1
- Wells, Christopher D1
Opioids
2 Results
- Symposium on pain medicine
Neuropathic Pain: Principles of Diagnosis and Treatment
Mayo Clinic ProceedingsVol. 90Issue 4p532–545Published in issue: April, 2015- Ian Gilron
- Ralf Baron
- Troels Jensen
Cited in Scopus: 297Neuropathic pain is caused by disease or injury of the nervous system and includes various chronic conditions that, together, affect up to 8% of the population. A substantial body of neuropathic pain research points to several important contributory mechanisms including aberrant ectopic activity in nociceptive nerves, peripheral and central sensitization, impaired inhibitory modulation, and pathological activation of microglia. Clinical evaluation of neuropathic pain requires a thorough history and physical examination to identify characteristic signs and symptoms. - SUPPLEMENT ARTICLE
Recommendations for the Pharmacological Management of Neuropathic Pain: An Overview and Literature Update
Mayo Clinic ProceedingsVol. 85Issue 3SupplementS3–S14Published in issue: March, 2010- Robert H. Dworkin
- Alec B. O'Connor
- Joseph Audette
- Ralf Baron
- Geoffrey K. Gourlay
- Maija L. Haanpää
- and others
Cited in Scopus: 1017The Neuropathic Pain Special Interest Group of the International Association for the Study of Pain recently sponsored the development of evidence-based guidelines for the pharmacological treatment of neuropathic pain. Tricyclic antidepressants, dual reuptake inhibitors of serotonin and norepinephrine, calcium channel α2-δ ligands (ie, gabapentin and pregabalin), and topical lidocaine were recommended as first-line treatment options on the basis of the results of randomized clinical trials. Opioid analgesics and tramadol were recommended as second-line treatments that can be considered for first-line use in certain clinical circumstances.